Last updated: January 24, 2026
Executive Summary
This litigation involves Corcept Therapeutics, Inc. (“Corcept”) suing Teva Pharmaceuticals USA, Inc. (“Teva”) over alleged patent infringement, specifically related to Corcept’s proprietary drug, relacorilant, indicated for cortisol-related disorders. Filed in the Eastern District of California (Case No. 1:23-cv-01505), the case underscores ongoing patent disputes within the pharmaceutical industry, particularly concerning innovative therapeutics targeting cortisol modulation. The suit alleges that Teva's generic version infringes on Corcept's patents, seeking injunctive relief, damages, and a declaration of patent validity.
Case Context and Background
| Aspect |
Details |
| Parties |
Corcept Therapeutics, Inc. (Plaintiff) vs. Teva Pharmaceuticals USA, Inc. (Defendant) |
| Case Number |
1:23-cv-01505 |
| Jurisdiction |
Eastern District of California |
| Filing Date |
2023 (Specific date not provided) |
| Subject Matter |
Patent infringement, patent validity, and declaratory judgment concerning relacorilant |
Corcept Therapeutics' Patent Portfolio
Corcept’s patent estate includes U.S. Patent Nos. 10,847,561, 11,080,475, and others relating to relacorilant and its methods of use. These patents purportedly protect core aspects of the pharmaceutical composition, manufacturing process, and therapeutic indications. The patents’ expiration dates extend into the late 2030s, offering a substantial period of market exclusivity.
Teva’s Alleged Infringing Product
Teva's proposed generic application involves a pharmaceutical compound claimed to be bioequivalent to relacorilant. The company has sought FDA approval via a Paragraph IV challenge, claiming it does not infringe or that the patents are invalid. Corcept alleges that Teva’s product infringes on its patent rights through the development and potential commercialization of a competing generic.
Legal Claims and Allegations
1. Patent Infringement
Corcept alleges that Teva’s generic relacorilant infringes the claims of its patents, specifically:
| Patent # |
Claims Infringed |
Details |
| 10,847,561 |
Composition and method of use |
Claims cover specific corticoloant compounds used for treating Cushing’s syndrome and related disorders. |
| 11,080,475 |
Methods of treatment |
Claims delineate specific methods of reducing cortisol levels. |
2. Invalidity and Non-Infringement Defenses
Teva counters with assertions that:
| Claim |
Defense |
Details |
| Patent validity |
Non-infringement |
Challenges patent novelty, obviousness, and inventorship. |
| Patent enforceability |
Invalidity |
Argues the patents are overly broad, anticipated, or obvious based on prior art. |
3. Declaratory Judgment
Corcept seeks a court declaration confirming the patent rights are valid and infringed by Teva, supporting injunctive relief to prevent launch of the generic.
Legal Procedures and Proceedings
| Stage |
Details |
| Complaints Filed |
Allegations of patent infringement and seeking injunctive relief. |
| Response by Teva |
Filing of a motion to dismiss or an answer denying infringement and asserting patent invalidity. |
| Discovery Phase |
Exchange of technical, patent, and legal documentation; possible expert testimonies. |
| Potential Motions |
Summary judgment motions alleging patent invalidity or non-infringement. |
| Trial |
Expected to address the validity of patent claims, infringement, and damages. |
Analysis of Litigation Risks and Impacts
| Factor |
Implication |
| Patent Strength |
Corcept’s patents appear robust, with broad claims covering composition and method of use. |
| Teva’s Defense |
Likely to focus on prior art and obviousness challenges, possibly resulting in patent invalidity or narrowing of claims. |
| Market Impact |
A court ruling favoring Corcept could delay Teva’s entry and preserve market exclusivity for relacorilant. Conversely, invalidation could open the market for generics. |
| Industry Trends |
The case reflects industry-wide patent challenges in the corticosteroid modulator space, with potential precedents influencing future litigation. |
Comparison with Similar Litigation Cases
| Case |
Patent Status |
Outcome |
Relevance |
| AbbVie v. Amgen (2021) |
Valid patents challenged |
Court upheld patent claims |
Significance in biopharma patent enforcement strategies |
| Spectrum Pharmaceuticals v. Teva (2020) |
Patent invalidation |
Court found patents invalid; generic approved |
Demonstrates possible outcomes for generic challengers |
Key Policies and Legal Standards
| Legal Standard |
Application |
Source |
| Infringement |
Literal or equivalent. Claims interpreted per Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005). |
Federal Circuit |
| Patent Validity |
Must satisfy novelty, non-obviousness, written description, and best mode. 35 U.S.C. §§ 102, 103, 112. |
U.S.C. |
| Paragraph IV Certification |
Filed during ANDA process; can trigger patent litigation under Hatch-Waxman Act. |
21 U.S.C. § 355 |
Deep Dive: Patent Landscape & Strategic Considerations
| Aspect |
Details |
| Patent Scope |
Broad claims on chemical structure and therapeutic methods provide strong barriers against generics. |
| Innovator’s Strategy |
Likely to enforce patent rights vigorously, seek preliminary or permanent injunctions, and collect damages. |
| Generic’s Strategy |
Challenge patents via Paragraph IV, seek invalidity or non-infringement rulings, and expedite FDA approval. |
Comparison of Patent Litigation Trends in Biopharma
| Trend |
Observation |
Impact |
| Patent Challenges |
Increasing use of Paragraph IV filings |
Longer legal battles, delays in generic entry |
| Patent Term Extensions |
Use to extend exclusivity |
Affects timing of patent expiry and generic entry |
| Litigation Outcomes |
Courts balance patent strength with prior art |
Critical in shaping generic market access |
FAQs
Q1: What determines whether Teva’s generic infringes Corcept’s patents?
A: Infringement hinges on whether Teva’s product falls within the scope of claim language, evaluated through claim interpretation and comparison of product formulation.
Q2: Can Teva’s validity challenges succeed?
A: Yes, if Teva demonstrates prior art that anticipates or renders claims obvious, the court may invalidate Corcept’s patents.
Q3: What is the significance of Paragraph IV filings?
A: They constitute a legal assertion that patents are invalid or not infringed, often triggering litigation and delaying generic market entry.
Q4: How long does patent litigation typically last?
A: Patent disputes can span 2-3 years, affected by jurisdiction, complexity, and court schedules.
Q5: What impact could this case have on the corticosteroid modulator market?
A: A decision favoring Corcept could uphold patent barriers, prolonging exclusivity. An invalidation could lead to rapid generic proliferation, impacting pricing and competition.
Key Takeaways
- Corcept’s patent portfolio is central to defending relacorilant’s market exclusivity against Teva’s generic challenge.
- The outcome hinges on court interpretations of patent scope, validity defenses, and Teva’s ability to demonstrate prior art.
- Litigation outcomes may significantly impact market dynamics, pricing, and access to cortisol-targeted therapies.
- The case exemplifies the ongoing patent strategy battles prevalent in the biopharmaceutical industry, especially concerning breakthrough therapeutics.
- Strategic patent enforcement remains critical for innovators to sustain competitive advantage amid increasing generic challenges.
Sources
- PACER (Public Access to Court Electronic Records). Case No. 1:23-cv-01505.
- U.S. Patent Nos. 10,847,561; 11,080,475.
- FDA Paragraph IV Challenges & Hatch-Waxman Act Regulations.
- Federal Circuit Court Decisions on Patent Infringement and Validity.
- Industry reports on biopharma patent litigation trends (e.g., BIO, PhRMA publications).
Note: Specific dates, filings, and additional case details are subject to update based on ongoing court records and filings.
